A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab With or Without Platinum-Based Combination Chemotherapy Versus Chemotherapy in Subjects With Advanced or Metastatic Urothelial Carcinoma

Trial Profile

A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab With or Without Platinum-Based Combination Chemotherapy Versus Chemotherapy in Subjects With Advanced or Metastatic Urothelial Carcinoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Bladder cancer; Urethral cancer; Urogenital cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-361
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 12 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 28 Mar 2017 Planned End Date changed from 1 Apr 2020 to 28 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top